August 08, 2022
An Illinois federal judge on Saturday refused to unwind Actavis' trial win over allegations that the company's Androderm testosterone drug caused a man's heart attack, saying that while Actavis' disclosure of a regulator's letter hours after trial was "fishy," the plaintiff had not proved the company needed to share it earlier.
August 17, 2021
An Illinois federal jury Tuesday sided with Actavis Inc. on all counts in a lawsuit brought by a man who claimed the company's testosterone replacement drug caused his heart attack and who sought nearly $80 million in damages.
August 13, 2021
Actavis Inc. is asking an Illinois federal judge to end its jury trial and give it a win in a suit alleging its testosterone replacement drugs caused a man's heart attack, saying the man has failed to make his case and no reasonable jury would find the company responsible.
August 05, 2021
Actavis improperly marketed its testosterone replacement therapy drug Androderm and ignored safety warnings from federal regulators and studies indicating that use of such products could lead to increased risk of adverse cardiovascular events as it sought to make the drug its "cash cow," an Illinois federal jury heard Thursday.
January 02, 2020
An Illinois federal judge has partially denied pharmaceutical giant Actavis' summary judgment motion and refused to bar certain expert testimony in what was to have been the first bellwether trial against that company over cardiovascular issues allegedly caused by a testosterone replacement therapy drug.